Protocol Ledger

NCT06450886 · Phase II/III · ACTIVE NOT RECRUITING

Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body Myositis

Interventional Phase II/III clinical trial protocol NCT06450886 sponsored by Abcuro in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-10-21 Enrollment: 270 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06450886
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)270 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06450886
Protocol FieldVerified Registry Value
NCT IdentifierNCT06450886
Consolidated Lead SponsorAbcuro
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II/III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment270 participants (ESTIMATED)
Registered Start Date2024-10-21
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI